German Biosafety Committee statement on Bt Maize
News Sep 02, 2009
The German Central Committee on Biological Safety (ZKBS) has taken the cultivation ban on Bt maize MON810 of April 2009 as an opportunity to review its risk assessment of the cultivation of Bt maize MON810 of 2007 and to subject six new studies on the impact of Bt maize on non-target organisms to a detailed assessment. These studies mostly comprise laboratory test and have partially been drawn on as decisive factors for the cultivation ban on MON810 ordered by the BMELV (Federal Ministry of Food, Agriculture and Consumer Protection). The studies have been conducted by Rosi-Marshall et al. (2007), Bøhn et al. (2008), Kramarz et al. (2007), Schmidt et al. (2009), Hofmann (2007) and Hofmann et al. (2009).
A scientific assessment of the study results has revealed that none of them confirm potential adverse effect on non-target organisms by MON810 under cultivation conditions. The assessment is also considering the fact that some of the studies are of scientifically lower quality. The conclusion of the ZKBS is in line with the expert assessment of a French author group (Ricroch et al., 2009) and the opinion of the EFSA (European Food Safety Authority) on the request for renewal MON810 (EFSA, 2009). Both documents regard the German ban as scientifically not justified.
The ZKBS states that the cultivation of MON810 has no adverse effect on the environment.
Habitat loss, habitat fragmentation and the loss of genetic diversity are the main factors driving the extinction of many wild species, and the few eastern massasauga rattlesnakes remaining in Illinois have certainly suffered two of the three. A long-term study of these snakes reveals, however, that – despite their alarming decline in numbers – they have retained a surprising amount of genetic diversity.READ MORE
Researchers have discovered a navigational gene in glass catfish called the electromagnetic-perceptive gene, or EPG, that responds to certain magnetic waves. These findings have the potential to revolutionize treatments for humans and help those who suffer from tremors related to Parkinson’s and seizures associated with epilepsy.